Expanding ACCESS: Transplant Strategy Boosts Survival in Blood Cancers, Offers Potential Savings

Why It Matters

By leveling the donor‑matching playing field, the ACCESS protocol improves equity in curative stem‑cell therapy and reduces the financial burden of severe GVHD, reshaping transplant economics and patient outcomes.

Key Takeaways

• Post‑transplant cyclophosphamide yields 86% 1‑year survival in <7/8 matches
• Mismatched unrelated donor access rises to 80‑99% for Black patients
• Peripheral blood stem cells simplify collection versus bone marrow
• PTCy regimen uses inexpensive, decades‑old chemotherapy drug
• Ongoing OPTIMIZE trial tests reduced PTCy dose to cut infections

Pulse Analysis

Hematopoietic stem cell transplantation has long been hampered by the scarcity of fully HLA‑matched donors, especially for minority populations whose genetic profiles are under‑represented in donor registries. Traditional graft‑versus‑host disease (GVHD) prophylaxis relied on calcineurin inhibitors and antimetabolites, which, when paired with mismatched donors, produced unacceptable mortality rates. The ACCESS trial reframed this paradigm by integrating post‑transplant cyclophosphamide (PTCy) with tacrolimus and mycophenolate, leveraging a drug approved over six decades ago to blunt alloreactive T‑cell activation without inflating costs. This innovation aligns with broader health‑system goals of expanding access while maintaining safety.

The multicenter phase 2 study enrolled 268 adults across 21 U.S. sites, predominantly treating acute leukemias and myelodysplastic syndromes. By using peripheral blood stem cells—a less invasive source than bone marrow—the trial achieved rapid graft acquisition and comparable engraftment kinetics. Survival outcomes surpassed historical benchmarks for mismatched transplants, with 86% overall survival in the <7/8 cohort and GVHD‑free, relapse‑free survival above 50%. Importantly, the trial’s demographic composition—61% non‑White participants—demonstrates that the regimen works across diverse genetic backgrounds, effectively neutralizing the HLA barrier that previously limited donor options for Black and Hispanic patients.

Beyond clinical efficacy, the ACCESS protocol offers compelling economic advantages. Cyclophosphamide is a low‑cost, widely available chemotherapy agent, allowing transplant centers to adopt the regimen without significant capital investment. Compared with emerging cellular therapies such as gene editing or CAR‑T, HSCT remains the most affordable curative option for both malignant and non‑malignant hematologic diseases. Ongoing studies like OPTIMIZE and ACCELERATE aim to refine dosing to mitigate infection risk, further enhancing the value proposition. As the U.S. population becomes increasingly diverse, scalable solutions like PTCy‑based prophylaxis are poised to become the new standard, delivering equitable, high‑quality care while containing costs.